These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31742901)

  • 1. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.
    Kasai T; Kojima Y; Ohmichi T; Tatebe H; Tsuji Y; Noto YI; Kitani-Morii F; Shinomoto M; Allsop D; Mizuno T; Tokuda T
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2489-2502. PubMed ID: 31742901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
    Kojima Y; Kasai T; Noto YI; Ohmichi T; Tatebe H; Kitaoji T; Tsuji Y; Kitani-Morii F; Shinomoto M; Allsop D; Teramukai S; Mizuno T; Tokuda T
    PLoS One; 2021; 16(11):e0260323. PubMed ID: 34843548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
    Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of CSF NfL and tau in ALS.
    Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
    J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
    Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
    Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.
    Scarafino A; D'Errico E; Introna A; Fraddosio A; Distaso E; Tempesta I; Morea A; Mastronardi A; Leante R; Ruggieri M; Mastrapasqua M; Simone IL
    J Neurol; 2018 Oct; 265(10):2353-2362. PubMed ID: 30116940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value.
    Noto Y; Shibuya K; Sato Y; Kanai K; Misawa S; Sawai S; Mori M; Uchiyama T; Isose S; Nasu S; Sekiguchi Y; Fujimaki Y; Kasai T; Tokuda T; Nakagawa M; Kuwabara S
    Amyotroph Lateral Scler; 2011 Mar; 12(2):140-3. PubMed ID: 21126161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.
    Verde F; Steinacker P; Weishaupt JH; Kassubek J; Oeckl P; Halbgebauer S; Tumani H; von Arnim CAF; Dorst J; Feneberg E; Mayer B; Müller HP; Gorges M; Rosenbohm A; Volk AE; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):157-164. PubMed ID: 30309882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Kasai T; Tokuda T; Ishigami N; Sasayama H; Foulds P; Mitchell DJ; Mann DM; Allsop D; Nakagawa M
    Acta Neuropathol; 2009 Jan; 117(1):55-62. PubMed ID: 18989684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
    Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
    JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.
    Gagliardi D; Faravelli I; Meneri M; Saccomanno D; Govoni A; Magri F; Ricci G; Siciliano G; Pietro Comi G; Corti S
    J Cell Mol Med; 2021 Apr; 25(8):3765-3771. PubMed ID: 33609080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.
    Benatar M; Wuu J; Andersen PM; Lombardi V; Malaspina A
    Ann Neurol; 2018 Jul; 84(1):130-139. PubMed ID: 30014505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential diagnosis of amyotrophic lateral sclerosis from Guillain-Barré syndrome by quantitative determination of TDP-43 in cerebrospinal fluid.
    Hosokawa M; Arai T; Yamashita M; Tsuji H; Nonaka T; Masuda-Suzukake M; Tamaoka A; Hasegawa M; Akiyama H
    Int J Neurosci; 2014 May; 124(5):344-9. PubMed ID: 24066851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.